Dark Watch | $3,500,000 | (Mar 17, 2026)
Alomana | $4,597,680 | (Mar 17, 2026)
Gangkhar | $4,250,000 | (Mar 17, 2026)
Certified by Founder
Lodge
Slate Medicines
start up
United States
- Raleigh, NC
- 25/02/2026
- Series A
- $130,000,000
Slate Medicines is a biotech company focused on advancing next generation therapeutics for migraine and other headache disorders. The Company’s lead program, SLTE-1009, is a potential best-in-class subcutaneous anti-PACAP for the prevention of migraine and other headache disorders. The company is backed by leading healthcare investors including RA Capital Management, Forbion, Foresite Capital, and an additional undisclosed biotech investor. For more information, please visit www.slatemedicines.com.
- Industry Biotechnology Research
- Website https://www.slatemedicines.com/
- LinkedIn https://www.linkedin.com/company/slate-medicines/
Malama Health | $9,200,000 | (Mar 17, 2026)
Great Sky | $14,000,000 | (Mar 17, 2026)
Understood Care | $5,000,000 | (Mar 17, 2026)
AgZen | $10,000,000 | (Mar 17, 2026)
Certiv | $4,200,000 | (Mar 17, 2026)
Scanner | $22,000,000 | (Mar 17, 2026)
Zero RFI | $13,800,000 | (Mar 17, 2026)
Nadia Care | $12,000,000 | (Mar 17, 2026)
Eileen Inc. | $1,000,000 | (Mar 17, 2026)
Halcyon(US) | $21,000,000 | (Mar 17, 2026)